Adenylate Kinase 3 Sensitizes Cells to Cigarette Smoke Condensate Vapor Induced Cisplatin Resistance

Abstract

BackgroundThe major established etiologic risk factor for bladder cancer is cigarette smoking and one of the major antineoplastic agents used for the treatment of advanced bladder cancer is cisplatin. A number of reports have suggested that cancer patients who smoke while receiving treatment have lower rates of response and decreased efficacy of cancer therapies.Methodology/Principal FindingsIn this study, we investigated the effect of cigarette smoke condensate (CSC) vapor on cisplatin toxicity in urothelial cell lines SV-HUC-1 and SCaBER cells. We showed that chronic exposure to CSC vapor induced cisplatin resistance in both cell lines. In addition, we found that the expression of mitochondrial-resident protein adenylate kinase-3 (AK3) is decreased by CSC vapor. We further observed that chronic CSC vapor-exposed cells displayed decreased cellular sensitivity to cisplatin, decreased mitochondrial membrane potential (ΔΨm) and increased basal cellular ROS levels compared to unexposed cells. Re-expression of AK3 in CSC vapor-exposed cells restored cellular sensitivity to cisplatin. Finally, CSC vapor increased the growth of the tumors and also curtail the response of tumor cells to cisplatin chemotherapy in vivo.Conclusions/SignificanceThe current study provides evidence that chronic CSC vapor exposure affects AK3 expression and renders the cells resistant to cisplatin.

A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma

“…Western blot analysis was carried out as described previously4548. Polyclonal rabbit anti-DYRK1A antibody was obtained from Santa cruz (Santa cruz biotechnology).…”

The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors

“…Polyclonal anti-Mig6 antibody was a generous gift from Dr. Ferby [15]. When appropriate, cells were cultured in serum free medium overnight, pretreated with the indicated inhibitors for 3 hrs or 24 hrs, and the treated with 10 ng/ml EGF for 10 or 30 min and immunoblot and immunoprecipitation analysis were performed as previously described [31].…”

FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients

“…These cisplatin-based regimens have been shown to improve the overall survival and quality of life for NSCLC patients [7]. Unfortunately, cisplatin resistance and dose-limiting side effects have been a challenge to further improve the efficacy of cisplatin-based chemotherapy in lung cancer [8][9][10][11]. Therefore, it is very important to understand the molecular mechanism of resistance to chemotherapeutic drugs, particularly platinum-containing drugs.…”